Protein-Protein Interaction Modulator

Inhibits actin polymerization

Inhibits RGS proteins, selective for RGS4

Oxaliplatin is a platinum-based DNA-cross-linking agent. It is a chemotherapeutic drug, often used in combination with leucovorin, fluorouracil, and capecitabine. Oxaliplatin works by cross-linking DNA thus inhibiting the synthesis of RNA and proteins, which leads to cell death and inhibition of cancer cells growth. It is more effective than cisplatin or irinotecan in treating metastatic cancer. Oxaliplatin also has effects on Toll-like receptor 4 (TLR4) expression levels in vitro and in vivo models. In addition, oxaliplatin's effect on ATP binding cassette transporter proteins may be responsible for its antitumour activity against solid tumours. Oxaliplatin is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

A chemical probe for the dual bromodomains of human transcription-initiation-factor TFIID subunit 1 (TAF1). GNE 371 binds TAF1 with an IC50 of 10 nM and is selective over other bromodomain family members. Exerts anti-proliferative effects in synergy with BET inhibitor JQ1.

Recombinant protein against VEGF(A); binds placental growth factor (PIGF)

Dual PI3K/mTOR inhibitor

Formyl peptide receptor-1 (FPR-1) antagonist

VS1 is a novel synthetic peptide, which is engineered to function as an antimicrobial agent. This peptide originates from recombinant DNA technology, providing a customizable approach to target specific microbial strains. Its mode of action involves the selective disruption of microbial cell membranes, leading to the lysis and consequent death of the target cell. The specificity of VS1 for microbial cells over mammalian cells minimizes off-target effects, making it a highly effective agent for infection control. The applications of VS1 are diverse within the scientific and medical communities. It is particularly useful in the study of microbial resistance, offering insights into the development of new antimicrobial therapies. VS1 has potential applications in clinical settings for treating infections resistant to traditional antibiotics. Researchers harness VS1 in laboratory experiments aimed at understanding microbial physiology and in developing new methods for microbial detection. Overall, VS1 serves as an invaluable tool for advancing the field of microbiology and infectious disease research, providing novel solutions to combat persistent and resistant microbial infections.

Iguratimod is a drug that is used to treat autoimmune and inflammatory conditions such as rheumatoid arthritis. This drug works by suppressing the activity of inflammatory cells and cytokines such as interleukin-1 and tumor necrosis factor-alpha (TNF-alpha). By reducing the levels of these cytokines, Iguratimod helps to alleviate inflammation and joint damage associated with conditions like rheumatoid arthritis. Iguratimod is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Levosimendan has been shown to act as a calcium sensitiser and increase cytosolic Ca2+ levels. It is an analog of the cardiac glycoside, ouabain. This drug has been shown to be effective for the treatment of congestive heart failure and is used to increase the heart’s contractility and decrease its rate in patients who have low cardiac output. Levosimendan also causes vasodilation by increasing nitric oxide production in vascular endothelial cells. Levosimendan is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Potent inhibitor of the interaction between defective cullin neddylation protein DCN1 and NEDD8-conjugating enzyme UBC12 with IC50 of 11 nM. WS 383 blocks the DCN1-UBC12 interaction in a reversible manner, selectively inhibits Cul3/1 neddylation and induces accumulation of p21, p27, and NRF2 proteins.

Docetaxel is an antineoplastic agent that is used to treat various cancers such as breast and prostate cancer. This drug interferes with the normal function of microtubule growth. It is an anti-mitotic drug used in chemotherapy. Research has shown that this drug also induces programmed cell death in cancer cells. Docetaxel is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ are in stock across our global warehouses for rapid delivery and ease of use.

Inhibits interaction between PD1 and PDL1 immune checkpoint proteins